阅读说明：本技术 作为ep4受体拮抗剂的(r)-4-(1-(1-(4-(三氟甲基)苄基)吡咯烷-2-甲酰胺)环丙基)苯甲酸 ((R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropyl) benzoic acid as EP4 receptor antagonists ) 是由 塞布丽娜·普奇 F·马科维 L·C·罗瓦蒂 于 2019-07-04 设计创作，主要内容包括：以下发明涉及(R)-4-(1-(1-(4-(三氟甲基)苄基)吡咯烷-2-甲酰胺)环丙基苯甲酸(化合物1)或其盐。还描述了用于获得化合物1的有利方法以及包含化合物1的药物组合物。(R)-4-(1-(1-(4-(三氟甲基)苄基)吡咯烷-2-甲酰胺)环丙基苯甲酸(化合物1)或其药学上可接受的盐被描述为用于作为EP4受体拮抗剂在治疗涉及前列腺素E-2(PGE-2)在其发病机理中的活性的病状的中使用。(The following invention relates to (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropanebenzoic acid (compound 1) or a salt thereof advantageous methods for obtaining compound 1 and pharmaceutical compositions comprising compound 1 are also described (R) -4- (1- (1- (4- (trifluoromethyl) benzyl) pyrrolidine-2-carboxamide) cyclopropanebenzoic acid (compound 1) or a pharmaceutically acceptable salt thereof is described for use as an EP4 receptor antagonist in the treatment of conditions involving prostaglandin E 2 (PGE 2 ) In the pathology of activity in its pathogenesis.)